NO20005672L - Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet - Google Patents

Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet

Info

Publication number
NO20005672L
NO20005672L NO20005672A NO20005672A NO20005672L NO 20005672 L NO20005672 L NO 20005672L NO 20005672 A NO20005672 A NO 20005672A NO 20005672 A NO20005672 A NO 20005672A NO 20005672 L NO20005672 L NO 20005672L
Authority
NO
Norway
Prior art keywords
antigen
attenuated salmonella
constitutively expressing
salmonella mutants
same
Prior art date
Application number
NO20005672A
Other languages
English (en)
Other versions
NO20005672D0 (no
Inventor
Fernando R Noriega
Marcelo Sztein
Myron M Levine
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of NO20005672D0 publication Critical patent/NO20005672D0/no
Publication of NO20005672L publication Critical patent/NO20005672L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20005672A 1998-05-13 2000-11-10 Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet NO20005672L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen
PCT/US1999/006554 WO1999058146A1 (en) 1998-05-13 1999-04-30 ATTENUATED MUTANTS OF SALMONELLA WHICH CONSTITUTIVELY EXPRESS THE Vi ANTIGEN

Publications (2)

Publication Number Publication Date
NO20005672D0 NO20005672D0 (no) 2000-11-10
NO20005672L true NO20005672L (no) 2001-01-15

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005672A NO20005672L (no) 1998-05-13 2000-11-10 Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet

Country Status (16)

Country Link
US (1) US6190669B1 (no)
EP (1) EP1076566B1 (no)
JP (1) JP4363782B2 (no)
AT (1) ATE333285T1 (no)
AU (1) AU754795B2 (no)
CA (1) CA2328056C (no)
DE (1) DE69932425T2 (no)
DK (1) DK1076566T3 (no)
ES (1) ES2268864T3 (no)
HU (1) HUP0101747A3 (no)
MX (1) MXPA00011075A (no)
NO (1) NO20005672L (no)
NZ (1) NZ508110A (no)
PL (1) PL192378B1 (no)
WO (1) WO1999058146A1 (no)
ZA (1) ZA200006381B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141427C (en) * 1992-07-31 2008-07-22 Mohammed Anjam Khan Expression of recombinant fusion proteins in attenuated bacteria
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
MXPA01005615A (es) * 1998-12-04 2004-08-19 Univ Manitoba Procedimiento de inmunizacion en dos pasos para proteger contra infeccion por chlamydia.
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
DK1112747T3 (da) * 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
MXPA02010407A (es) * 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
DE60319822T2 (de) * 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
AU2006308966A1 (en) * 2005-10-28 2007-05-10 University Of Maryland, Baltimore Attenuated salmonella enterica Serovar Paratyphi A and uses thereof
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
US20110052635A1 (en) * 2006-03-20 2011-03-03 Vrije Universiteit Brussel Live attenuated salmonella vaccine
EP2004802A1 (en) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Live attenuated salmonella vaccine
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
BRPI0818736A2 (pt) * 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CA3231738A1 (en) * 2021-09-10 2023-03-16 Regents Of The University Of Minnesota Salmonella engineered for nontoxic colonization of tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
NZ508110A (en) 2002-10-25
ZA200006381B (en) 2002-02-07
EP1076566B1 (en) 2006-07-19
DE69932425T2 (de) 2007-03-08
HUP0101747A3 (en) 2002-03-28
CA2328056C (en) 2010-07-06
ATE333285T1 (de) 2006-08-15
US6190669B1 (en) 2001-02-20
EP1076566A1 (en) 2001-02-21
PL192378B1 (pl) 2006-10-31
HUP0101747A2 (hu) 2001-09-28
JP4363782B2 (ja) 2009-11-11
WO1999058146A1 (en) 1999-11-18
DK1076566T3 (da) 2006-11-13
JP2002514398A (ja) 2002-05-21
MXPA00011075A (es) 2002-04-24
DE69932425D1 (de) 2006-08-31
PL344593A1 (en) 2001-11-05
AU3740599A (en) 1999-11-29
AU754795B2 (en) 2002-11-28
CA2328056A1 (en) 1999-11-18
ES2268864T3 (es) 2007-03-16
EP1076566A4 (en) 2005-01-05
NO20005672D0 (no) 2000-11-10

Similar Documents

Publication Publication Date Title
NO20005672D0 (no) Svekkede Salmonella-mutanter som uttrykker Vi-antigenet konstitutivt
EP1032417A4 (en) BACTERIAL VACCINES, CONTAINING AUXOTROPHIC DELAYED LISTERIA STRAINS, WHICH HETEROLOGIST EXPRESS ANTIGENS
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK142391A (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
DZ1763A1 (fr) Composition vaccinantes.
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
AU9094191A (en) Recombinant avirulent salmonella antifertility vaccines
DK1326633T3 (da) Sammensætning omfattende immunogene mikropartikler
MX9203852A (es) Composicion selladora acrilica mejorada, y metodos relacionados con la misma.
TR200401569T4 (tr) Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
NO910739D0 (no) Sementeringsmateriale for olje, gass- og vannbroenner.
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
DE69105285D1 (de) Gegen Wärme vakuumisolierter Behälter.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DE3873278D1 (de) Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
FI911258A0 (fi) Foer kylmaskin, i synnerhet foer hushaollskylskaop avsedd plaotkondensator.
FI900713L (fi) Trycksaeker skalkonstruktion foer undervattensteknik, i synnerhet foer djuphavsteknik.
AU3487799A (en) Improved live attenuated viruses for use as vectors or vaccines
FI912699A0 (fi) Expenderingskropp, saerskilt foer massautloppslaodan i en pappersmaskin.
SU979504A1 (ru) Щтамм НАГ-фага 93,Ф-98,лизирующий НАГ-вибрионы 0-8 серотипа
IT8223644A0 (it) Serracavo, particolarmente per elettrodomestici o simili.
IT1238603B (it) Valvola cardiaca artificiale, con elevatissimo grado di sicurezza
WO1999027955A3 (en) Treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application